EUVIMEDEUVIMED entdecken
Open Access

Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy

Clara Diaz Garcia-Prada, Léna Carmes, Salima Atis, Ali Parach, Alejandro Bertolet, Marta Jarlier, Sophie Poty, Daniel Suarez Garcia, Wook-Geun Shin, Stanislas Du Manoir, Jan Schuemann, Olivier Tillement und 3 weitere

Journal of Nuclear Medicine · 2023

DOI: 10.2967/jnumed.123.265418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Clara Diaz Garcia-Prada und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Recherche en Cancérologie de Montpellier, Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellie…. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Ovarian Neoplasms, Nanoparticles. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer (OC) is the most lethal gynecologic malignancy (5-y overall survival rate, 46%). OC is generally detected when it has already spread to the peritoneal cavity (peritoneal carcinomatosis). This study investigated whether gadolinium-based nanoparticles (Gd-NPs) increase the efficacy of targeted radionuclide therapy using [177Lu]Lu-DOTA-trastuzumab (an antibody against human epidermal growth factor receptor 2). Gd-NPs have radiosensitizing effects in conventional external-beam radiotherapy and have been tested in clinical phase II trials.

Methods

First, the optimal activity of [177Lu]Lu-DOTA-trastuzumab (10, 5, or 2.5 MBq) combined or not with 10 mg of Gd-NPs (single injection) was investigated in athymic mice bearing intraperitoneal OC cell (human epidermal growth factor receptor 2-positive) tumor xenografts. Next, the therapeutic efficacy and toxicity of 5 MBq of [177Lu]Lu-DOTA-trastuzumab with Gd-NPs (3 administration regimens) were evaluated. NaCl, trastuzumab plus Gd-NPs, and [177Lu]Lu-DOTA-trastuzumab alone were used as controls. Biodistribution and dosimetry were determined, and Monte Carlo simulation of energy deposits was performed. Lastly, Gd-NPs' subcellular localization and uptake, and the cytotoxic effects of the combination, were investigated in 3 cancer cell lines to obtain insights into the involved mechanisms.

Results

The optimal [177Lu]Lu-DOTA-trastuzumab activity when combined with Gd-NPs was 5 MBq. Moreover, compared with [177Lu]Lu-DOTA-trastuzumab alone, the strongest therapeutic efficacy (tumor mass reduction) was obtained with 2 injections of 5 mg of Gd-NPs/d (separated by 6 h) at 24 and 72 h after injection of 5 MBq of [177Lu]Lu-DOTA-trastuzumab. In vitro experiments showed that Gd-NPs colocalized with lysosomes and that their radiosensitizing effect was mediated by oxidative stress and inhibited by deferiprone, an iron chelator. Exposure of Gd-NPs to 177Lu increased the Auger electron yield but not the absorbed dose.

Conclusion

Targeted radionuclide therapy can be combined with Gd-NPs to increase the therapeutic effect and reduce the injected activities. As Gd-NPs are already used in the clinic, this combination could be a new therapeutic approach for patients with ovarian peritoneal carcinomatosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal NeoplasmsOvarian NeoplasmsNanoparticlesMiceAnimalsHumansFemaleRadioisotopesGadoliniumTissue DistributionTrastuzumabRadioimmunotherapyLutetiumCell Line, Tumor

Stichwörter der Autor:innen

Auger electronsTRTovarian cancerradioimmunotherapyradiopharmaceuticalradiosensitization

Substanzen

RadioisotopesGadoliniumTrastuzumabLutetium

Autor:innen und Institutionen

  • Institut de Recherche en Cancérologie de Montpellier, Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France.
  • Institut Lumière Matière, Université Claude Bernard Lyon 1, Villeurbanne, France.
  • NH TherAguix S.A., Meylan, France.
  • Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Biometrics Unit, Montpellier Cancer Institute, University of Montpellier, Montpellier, France; and.
  • Institut Universitaire de France, Paris, France.

Förderung

  • NCI NIH HHS

Zitieren

APA

Garcia-Prada, C. D., Carmes, L., Atis, S., Parach, A., Bertolet, A., Jarlier, M., Poty, S., Garcia, D. S., Shin, W. G., Du Manoir, S., Schuemann, J., Tillement, O., Lux, F., Constanzo, J., & Pouget, J. P. (2023). Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.265418

Vancouver

Garcia-Prada CD, Carmes L, Atis S, Parach A, Bertolet A, Jarlier M, et al. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.265418

BibTeX
@article{GarciaPrada2023,
  author = {Garcia-Prada, Clara Diaz and Carmes, Léna and Atis, Salima and Parach, Ali and Bertolet, Alejandro and Jarlier, Marta and Poty, Sophie and Garcia, Daniel Suarez and Shin, Wook-Geun and Du Manoir, Stanislas and Schuemann, Jan and Tillement, Olivier and Lux, François and Constanzo, Julie and Pouget, Jean-Pierre},
  title = {Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  doi = {10.2967/jnumed.123.265418}
}
Kostenlos starten →